Monday, October 5, 2026

11:15 AM - 12:00 PM

Zlotnik Ballroom

---

Overview

Peptides are everywhere — in compounding pharmacies, med spas, concierge practices, and direct-to-consumer wellness platforms. Yet many health care providers and their counsel remain uncertain about what peptides actually are, whether they are lawful, and how regulators are beginning to close in. This session provides a practical roadmap for health law practitioners advising clients in this rapidly evolving space. We will start with the science — what peptides are, how they differ from traditional pharmaceuticals and biologics, and why they have become a focal point of the wellness and anti-aging industries. From there, we walk through the most common peptides in clinical use, including BPC-157, semaglutide, and tirzepatide, and the ways they are prescribed, compounded, and marketed. The session then turns to the regulatory framework: how FDA, DEA, and state medical and pharmacy boards assert jurisdiction, with particular attention to compounding and the 503A/503B landscape. A candid look at recent FDA warning letters, DEA actions, state board investigations, and civil litigation will help attendees anticipate where enforcement is headed. The presentation concludes with practical risk management strategies counsel can deploy when advising physicians, compounders, med spas, and health systems. Whether your clients are already in the peptide space or you are fielding new inquiries, you will leave with a framework to analyze each situation and a checklist of issues to raise.

---